The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors

por Hou, Helei, Sun, Dantong, Zhang, Xiaochun
Publicado 2019

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient

por Tao, Junyan, Sun, Dantong, Hou, Helei
Publicado 2020

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis

por Sun, Dantong, Hou, Helei, Zhang, Chuantao, Zhang, Xiaochun
Publicado 2018

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma

por Sun, Dantong, Liu, Dong, Liu, Qiaoling, Hou, Helei
Publicado 2020

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer

por Sun, Dantong, Teng, Fei, Xing, Puyuan, Li, Junling
Publicado 2021

Advancement in research and therapy of NF1 mutant malignant tumors

por Tao, Junyan, Sun, Dantong, Dong, Lina, Zhu, Hua, Hou, Helei
Publicado 2020

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing

por Sun, Dantong, Yan, Weihua, Zhu, Hua, Liu, Qiaoling, Hou, Helei
Publicado 2020

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer

por Hou, Helei, Sun, Dantong, Zhang, Chuantao, Liu, Dong, Zhang, Xiaochun
Publicado 2021

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma

por Sun, Dantong, Zhao, Han, Zhou, Hai, Tao, Junyan, Li, Tianjun, Zhu, Jingjuan, Hou, Helei
Publicado 2023

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

por Sun, Dantong, Zhu, Yan, Zhu, Jingjuan, Tao, Junyan, Wei, Xiaojuan, Wo, Yang, Hou, Helei
Publicado 2020

ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production

por Sun, Dantong, Qian, Haili, Wang, Jinsong, Xie, Tongji, Teng, Fei, Li, Junling, Xing, Puyuan
Publicado 2022

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

por Sun, Dantong, Tian, Lu, Zhu, Yan, Wo, Yang, Liu, Qiaoling, Liu, Shihai, Li, Hong, Hou, Helei
Publicado 2020

The role of CD28 in the prognosis of young lung adenocarcinoma patients

por Sun, Dantong, Tian, Lu, Bian, Tiantian, Zhao, Han, Tao, Junyan, Feng, Lizong, Liu, Qiaoling, Hou, Helei
Publicado 2020

Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency

por Sun, Dantong, Feng, Feiyue, Teng, Fei, Xie, Tongji, Wang, Jinsong, Xing, Puyuan, Qian, Haili, Li, Junling
Publicado 2023

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis

por Hou, Helei, Sun, Dantong, Liu, Kewei, Jiang, Man, Liu, Dong, Zhu, Jingjuan, Zhou, Na, Cong, Jing, Zhang, Xiaochun
Publicado 2019

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification

por Sun, Dantong, Tao, Junyan, Yan, Weihua, Zhu, Jingjuan, Zhou, Hai, Sheng, Yingying, Xue, Chaofan, Li, Hong, Hou, Helei
Publicado 2022

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer

por Sun, Dantong, Wu, Weizheng, Wang, Li, Qu, Jialin, Han, Qiman, Wang, Huiyun, Song, Shanai, Liu, Ning, Wang, Yongjie, Hou, Helei
Publicado 2023